Abstract
The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.
Keywords: Cell, Cancer, Cetuximab, Food and Drug Association, Cytotoxic T lymphocytes, Epidermal growth factors.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Cetuximab and the Head and Neck Squamous Cell Cancer
Volume: 18 Issue: 3
Author(s): Riccardo Concu*M. Natalia D.S. Cordeiro*
Affiliation:
- REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto,Portugal
- REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto,Portugal
Keywords: Cell, Cancer, Cetuximab, Food and Drug Association, Cytotoxic T lymphocytes, Epidermal growth factors.
Abstract: The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.
Export Options
About this article
Cite this article as:
Concu Riccardo *, Cordeiro Natalia D.S. M. *, Cetuximab and the Head and Neck Squamous Cell Cancer, Current Topics in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1568026618666180112162412
DOI https://dx.doi.org/10.2174/1568026618666180112162412 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death
Current Topics in Medicinal Chemistry Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design A Review on Structures and Functions of Bcl-2 Family Proteins from Homo sapiens
Protein & Peptide Letters Solid Lipid Nanoparticles Containing Nimesulide: Preparation, Characterization and Cytotoxicity Studies
Current Nanoscience Cancer Biomarker Discovery for Precision Medicine: New Progress
Current Medicinal Chemistry At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine Vitiligo: Pathogenetic Hypotheses and Targets for Current Therapies
Current Drug Metabolism Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Understanding the Monoclonal Antibody Involvement in Targeting the Activation of Tumor Suppressor Genes
Current Topics in Medicinal Chemistry Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Anesthesia Issues in Central Nervous System Disorders
Current Aging Science How Recent Patents Have Changed our Clinical Approach in Cardio-Thoracic Surgery
Recent Patents on Regenerative Medicine New Prospects for Nelfinavir in Non-HIV-Related Diseases
Current Molecular Pharmacology Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets Development of Metal-Based Drugs and Application in Clinical Treatment
The Natural Products Journal Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Plasticity of T Cell Differentiation and Cytokine Signature: A Double-Edged Sword for Immune Responses
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton
Anti-Cancer Agents in Medicinal Chemistry Injectable Thermosensitive Chitosan/Glycerophosphate-Based Hydrogels for Tissue Engineering and Drug Delivery Applications: A Review
Recent Patents on Drug Delivery & Formulation